VYNE Therapeutics Inc. (VYNE)
Largest Insider Buys in Sector
VYNE Stock Price History Chart
VYNE Stock Performance
About VYNE Therapeutics Inc.
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various …
Insider Activity of VYNE Therapeutics Inc.
Over the last 12 months, insiders at VYNE Therapeutics Inc. have bought $0 and sold $0 worth of VYNE Therapeutics Inc. stock.
On average, over the past 5 years, insiders at VYNE Therapeutics Inc. have bought $6.91M and sold $5.32M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 13,000 shares for transaction amount of $50,778 was made by LEPORE PATRICK G (director) on 2023‑11‑15.
List of Insider Buy and Sell Transactions, VYNE Therapeutics Inc.
| 2023-11-15 | director | 13,000 0.3748% | $3.91 | $50,778 | -46.95% | |||
| 2021-11-30 | director | 12,500 0.024% | $1.02 | $12,699 | -55.58% | |||
| 2021-08-25 | director | 12,500 0.0243% | $1.60 | $20,000 | -62.28% | |||
| 2021-08-16 | Sale | 10 percent owner | 250,000 0.4697% | $1.74 | $435,000 | -64.78% | ||
| 2021-08-13 | Sale | 10 percent owner | 250,000 0.4967% | $1.84 | $460,000 | -64.61% | ||
| 2021-08-12 | Sale | 10 percent owner | 338,897 0.7299% | $2.23 | $755,740 | -68.34% | ||
| 2021-05-26 | director | 12,500 0.0241% | $3.60 | $44,958 | -68.32% | |||
| 2021-05-06 | Sale | 10 percent owner | 1M 2.0052% | $3.67 | $3.67M | -65.17% | ||
| 2021-03-15 | director | 12,500 0.0259% | $7.41 | $92,563 | -79.34% | |||
| 2021-01-28 | 10 percent owner | 4.22M 2.2941% | $2.37 | $10M | -69.62% | |||
| 2020-12-03 | director | 100,000 0.078% | $1.71 | $170,850 | -46.15% | |||
| 2020-09-08 | President and CEO | 150,000 0.084% | $1.38 | $207,135 | +10.54% | |||
| 2020-09-08 | Chief Financial Officer | 80,000 0.0474% | $1.46 | $116,960 | +10.54% | |||
| 2020-06-09 | 10 percent owner | 5.41M 3.4508% | $1.85 | $10M | -19.14% | |||
| 2018-07-24 | Sale | 1M 4.3407% | $7.65 | $7.65M | -11.34% | |||
| 2018-01-25 | 10 percent owner | 200,000 0.6735% | $17.00 | $3.4M | -71.72% | |||
| 2018-01-25 | 10 percent owner | 530,000 1.7848% | $17.00 | $9.01M | -71.72% | |||
| 2018-01-25 | 10 percent owner | 588,236 1.9809% | $17.00 | $10M | -71.72% | |||
| 2018-01-25 | director | 588,236 1.9809% | $17.00 | $10M | -71.72% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | 10 percent owner | 4935057 33.4548% | $2.50 | 2 | 4 | <0.0001% |
| Remeditex Ventures LLC | 10 percent owner | 1582854 10.7302% | $2.50 | 1 | 0 | |
| Domzalski David | President and CEO | 1315966 8.921% | $2.50 | 1 | 0 | +10.54% |
| Saik Andrew | Chief Financial Officer | 340000 2.3049% | $2.50 | 1 | 0 | +10.54% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 265000 1.7964% | $2.50 | 1 | 0 |
Institutional Investor Ownership
| Cormorant Asset Management Lp | $4.28M | 9.6 | 1.39M | 0% | +$0 | 0.2 | |
| Eventide Asset Management | $3.13M | 9.6 | 1.39M | 0% | +$0 | 0.05 | |
| Citadel Advisors LLC | $3.63M | 8.13 | 1.18M | 0% | +$0 | <0.01 | |
| Dsc Advisors L P | $2.14M | 4.79 | 696,465 | 0% | +$0 | 3.46 | |
| Parkman Healthcare Partners Llc | $2.14M | 4.79 | 696,470 | 0% | +$0 | 0.27 |